#ESMO25: Amgen, Zai Lab detail reduced survival benefit in stomach cancer trial news2025-10-19T22:05:02+00:00October 19th, 2025|Endpoints News|
#ESMO25: Akeso, Summit detail ivonescimab win in China for frontline lung cancernews2025-10-19T14:30:33+00:00October 19th, 2025|Endpoints News|
#ESMO25: Datroway, Trodelvy contest in triple negative breast cancer heats upnews2025-10-19T08:14:23+00:00October 19th, 2025|Endpoints News|
#ESMO25: Boehringer, Bayer are neck-and-neck in front-line HER2-mutant lung cancernews2025-10-18T15:00:14+00:00October 18th, 2025|Endpoints News|
#ESMO25: Padcev-Keytruda combo extends survival in Phase 3 bladder cancer trialnews2025-10-18T14:30:51+00:00October 18th, 2025|Endpoints News|
#ESMO25: Enhertu could move into ‘curative’ breast cancer setting on the strength of Phase 3 datanews2025-10-18T14:30:08+00:00October 18th, 2025|Endpoints News|
#ESMO25: BioNTech stops further work on cancer vaccine in advanced melanomanews2025-10-18T14:11:16+00:00October 18th, 2025|Endpoints News|
#ESMO25: Celcuity details Phase 3 breast cancer win as it works on FDA submissionnews2025-10-18T08:30:30+00:00October 18th, 2025|Endpoints News|
#ESMO25: Roche’s SERD is the first shown to work in non-mutant breast cancer patientsnews2025-10-18T05:00:27+00:00October 18th, 2025|Endpoints News|
#ESMO25: Grail’s cancer test better at spotting real cases as FDA filing nearsnews2025-10-17T22:05:05+00:00October 17th, 2025|Endpoints News|
